Applied Biosystems last week launched its TaqMan microRNA assays, thrusting the firm into an emerging niche market that has yet to establish a dominant player.

ABI is banking on its broad market reach, reputation of TaqMan, and currently installed instrument base to establish a presence in the microRNA market. In addition, the firm should be able to take advantage of its collaboration with noted genetics and microRNA researcher Victor Ambros of Dartmouth University to raise its profile among researchers in the field.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.